Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for NVS and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for NVS and 80,000+ other tickers.
See exactly how NVS's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for NVS and 80,000+ other tickers.
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
Axiom Investment Management LLC purchased a new stake in shares of Novartis AG (NYSE: NVS) in the first quarter, according to its most recent filing with the SEC. The firm purchased 3,326 shares of the company's stock, valued at approximately $508,000. Several other hedge funds have also recently bought and sold shares of
Ashton Thomas Securities LLC purchased a new stake in Novartis AG (NYSE: NVS) during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 22,962 shares of the company's stock, valued at approximately $3,507,000. A number of other institutional investors have also recently
These companies' recent headwinds shouldn't lead to decreased payouts.
Entropy Technologies LP acquired a new position in shares of Novartis AG (NYSE: NVS) in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 12,359 shares of the company's stock, valued at approximately $1,888,000. A number of other large
Cetera Investment Advisers grew its position in shares of Novartis AG (NYSE: NVS) by 13.5% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 203,045 shares of the company's stock after acquiring an additional 24,096 shares during the quarter.